IPOs

So you think you can go public? Few biotechs dance with Wall Street
So you think you can go public? Few biotechs dance with Wall Street
Fierce Biotech
biotech
IPOs
Structure Therapeutics
Mineralys Therapeutics
Coya Therapeutics
Flag link:
Acelyrin makes a splash with IPO, biopharma expects to raise $540M
Acelyrin makes a splash with IPO, biopharma expects to raise $540M
Medical Marketing and Media
Acelyrin
IPOs
Flag link:
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
BioPharma Dive
Acelyrin
IPOs
Kenvue
Flag link:
J&J sets top price for consumer health unit Kenvue’s IPO
J&J sets top price for consumer health unit Kenvue’s IPO
Pharmaphorum
JNJ
spinoff
Kenvue
IPOs
consumer health
Flag link:
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
CNBC
JNJ
consumer health
IPOs
Kenvue
spinoffs
Flag link:
IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid
IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid
BioSpace
Acelyrin
IPOs
immunology
Flag link:
After a record run, fewer biotechs are going public. Here’s how they’re performing.
After a record run, fewer biotechs are going public. Here’s how they’re performing.
BioPharma Dive
biotech
IPOs
Flag link:
Floating biotechs prompt tiny sparks of hope
Floating biotechs prompt tiny sparks of hope
EP Vantage
IPOs
biotech
Mineralys Therapeutics
Structure Therapeutics
Genelux
Cadrenal Therapeutics
Flag link:
BioXcel takes surprising path with IPO of oncology spinout OnkosXcel
BioXcel takes surprising path with IPO of oncology spinout OnkosXcel
Fierce Biotech
BioXcel
IPOs
oncology
OnkosXcel
Flag link:
IPOs vs SPACs
IPOs vs SPACs
EP Vantage
IPOs
SPAC
Belite Bio
Cerevel Therapeutics
NewAmsterdam Pharma
Nuvectis Pharma
Oculis
Roivant Sciences
Flag link:
A small Connecticut biotech throws hat into IPO ring
A small Connecticut biotech throws hat into IPO ring
Endpoints
Azitra
IPOs
skin diseases
dermatology
Flag link:
IPO Doors Creak Open as Mineralys Seeks $192M
IPO Doors Creak Open as Mineralys Seeks $192M
BioSpace
IPOs
Mineralys Therapeutics
hypertension
MLS-101
Flag link:
Swiss rare disease biotech withdraws IPO to update its Nasdaq plans
Swiss rare disease biotech withdraws IPO to update its Nasdaq plans
Endpoints
Relief Therapeutics
IPOs
Flag link:
Biotech startup Structure pulls off rare IPO, raising $161M
Biotech startup Structure pulls off rare IPO, raising $161M
BioPharma Dive
IPOs
Structure Therapeutics
Flag link:
Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report
Biotech CFOs eye research cuts, partnerships amid sector retrenchment: report
BioPharma Dive
biotech
CFOs
R&D
funding
IPOs
Flag link:
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Fierce Biotech
IPOs
Mineralys
hypertension
Flag link:
5 questions facing emerging biotech in 2023
5 questions facing emerging biotech in 2023
BioPharma Dive
biotech
IPOs
platform companies
funding
restructuring
Inflation Reduction Act
Flag link:
Ready for takeoff: J&J's consumer health unit Kenvue files for official separation
Ready for takeoff: J&J's consumer health unit Kenvue files for official separation
Endpoints
JNJ
IPOs
consumer health
Kenvue
spinoffs
Flag link:
IPOs fail to bounce back in Q4
IPOs fail to bounce back in Q4
EP Vantage
IPOs
Prime Medicine
Acrivon Therapeutics
Lipella Pharmaceuticals
Flag link:
Disappearing IPOs, building startups and closing deals: Views from an up-and-down year in biotech
Disappearing IPOs, building startups and closing deals: Views from an up-and-down year in biotech
BioPharma Dive
IPOs
venture capital
funding
Flag link:

Pages